Bristol/Agios AML Drug Idhifa Fails In Phase III
IDHENTIFY Studied The IDH2 Inhibitor In Its Approved Indication
Idhifa is approved in the US for relapsed or refractory AML patients with IDH2 mutations based on Phase I/II complete responses but did not meet the overall survival endpoint in the Phase III IDHENTIFY.
